Zenas Biopharma, Inc. (ZBIO) Stock Price & Analysis
Zenas Biopharma, Inc. (ZBIO) rose 4.60% to USD 18.42 as of June 10, 2026 at 03:16 UTC, according to Nexqual real-time market data.
ZBIO last closed at USD 17.61; the session ranged USD 17.38–18.55 on volume of 334,256 shares. Market capitalization is $1.16B, with a 52-week range of USD 8.91–44.6 (NMS). Source: Nexqual, June 10, 2026 at 03:16 UTC.
Key Statistics (as of June 10, 2026 at 03:16 UTC)
| Price | USD 18.42 |
|---|---|
| Change | ▲ 4.60% (up) |
| Previous Close | USD 17.61 |
| Open | USD 17.79 |
| Day Range | USD 17.38 – 18.55 |
| 52-Week Range | USD 8.91 – 44.6 |
| Volume | 334,256 shares |
| Market Cap | $1.16B |
| Exchange | NMS |
Technical Analysis (ZBIO)
Nexqual's technical model rates ZBIO "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.79 (neutral) |
| vs SMA50 | Below (USD 19.5) |
| MACD | -0.54 (negative) |
Analyst Ratings (ZBIO)
Wall Street analysts rate ZBIO "Strong Buy" based on 8 analysts, with a mean price target of USD 42.13 (range USD 22–55), per Nexqual as of June 10, 2026 at 03:16 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 42.13 |
| High Target | USD 55 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ZBIO)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.76 |
| Revenue Estimate | $15.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.46 vs est -1.54 ▲ beat |
| 2025-12-31 | USD -1.39 vs est -1.19 ▼ miss |
| 2025-09-30 | USD -1.22 vs est -0.85 ▼ miss |
| 2025-06-30 | USD -1.25 vs est -1.06 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:16 UTC.
Financials & Fundamentals (ZBIO)
| Total Revenue | $0 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -137.11% |
| Debt / Equity | 79.45 |
| Current Ratio | 11.94 |
| Total Cash | $717.20M |
| Total Debt | $266.83M |
| Free Cash Flow | $-166.29M |
Source: Nexqual, June 10, 2026 at 03:16 UTC.
Financial Health Score (ZBIO)
Nexqual rates Zenas Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:16 UTC.
| Growth | Strong — Revenue +100% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Mixed — $717M cash vs $267M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$166M, burning cash |
| Efficiency | Critical — ROE -137%, ROA -29.1% |
Ownership (ZBIO)
| Insider Ownership | +23.20% |
|---|---|
| Institutional Ownership | +90.43% |
| Shares Outstanding | 63.13M |
| Float | 39.62M |
| Short % of Float | +25.69% |
Source: Nexqual, June 10, 2026 at 03:16 UTC.
Leadership (ZBIO)
Zenas Biopharma, Inc. is led by Leon Oliver Moulder Jr. (age 68), Founder, CEO & Chairman, per Nexqual as of June 10, 2026 at 03:16 UTC.
| Founder, CEO & Chairman | Leon Oliver Moulder Jr. (age 68) |
|---|---|
| COO & President | Joseph L. Farmer (age 53) |
| Chief Business Officer & CFO | Jennifer A. Fox (age 53) |
| Chief Scientific Officer | Haley Laken |
Major Backers & Investors (ZBIO)
Notable institutional backers of Zenas Biopharma, Inc. include FMR, LLC, Federated Hermes, Inc., SR One Capital Management, LP, according to Nexqual as of June 10, 2026 at 03:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.39% |
| Federated Hermes, Inc. | 9.5% |
| SR One Capital Management, LP | 7.98% |
| NEA Management Company, LLC | 6.37% |
| Enavate Sciences Gp, LLC | 6.21% |
| Fidelity | 5.75% |
| Polar Capital Holdings PLC | 4.04% |
| Capital International Investors | 3.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.1% |
Source: Nexqual, June 10, 2026 at 03:16 UTC.
From Zenas Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- We also intend to submit a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") in the second half of 2026.
Partnerships
- In addition, in October 2024, we entered into a novation agreement with Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), under which we transferred to Tenacia our rights and obligations under our agreements with Dianthus Therapeutics Inc. ("Dianthus") for ZB005 (the "Tenacia Agreement").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| BCAX | Bicara Therapeutics Inc. | USD 20.56 | ▲ 2.8% |
| UPB | Upstream Bio, Inc. | USD 6.69 | ▼ 5.11% |
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| RAPP | Rapport Therapeutics, Inc. | USD 35.84 | ▼ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:16 UTC. This page is informational and not investment advice.